Expanded biomarker analysis of an international, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).

Bibliographic Details
Title:	Expanded biomarker analysis of an international, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).
Authors:	El-Khoueiry, Anthony B., Balli, David, Blanc, Jean-Frédéric, Rosmorduc, Olivier, Decaens, Thomas, Mathurin, Philippe, Merle, Philippe, Dayyani, Farshid, Masi, Gianluca, Pressiani, Tiziana, Galle, Peter Robert, Hatogai, Ken, Mueller, Udo, Kalambakas, Stacey Anastasia, Weispfenning, Anke, Ishii, Yuko, Bouattour, Mohamed
Source:	Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p635-635, 132p
Database:	Supplemental Index

More Details
ISSN:	0732183X
DOI:	10.1200/JCO.2025.43.4_suppl.635
Published in:	Journal of Clinical Oncology
Language:	English